Several brokerages have updated their recommendations and price targets on shares of Omega Therapeutics (NASDAQ: OMGA) in the last few weeks: 5/24/2022 – Omega Therapeutics had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $7.00 to $4.00. They now have a “neutral” rating on the stock. 5/24/2022 – Omega Therapeutics […]
Omega Therapeutics (NASDAQ:OMGA – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Tuesday, Zacks.com reports. According to Zacks, “Omega Therapeutics Inc. is a development-stage biotechnology company. Its OMEGA Epigenomic Programming(TM) platform harness the power of epigenetics to develop a new class of […]
Omega Therapeutics (NASDAQ:OMGA – Get Rating) had its price target reduced by investment analysts at The Goldman Sachs Group from $7.00 to $4.00 in a report issued on Tuesday, Stock Target Advisor reports. The brokerage presently has a “neutral” rating on the stock. The Goldman Sachs Group’s price objective points to a potential upside of […]
Wall Street brokerages predict that Omega Therapeutics, Inc. (NASDAQ:OMGA – Get Rating) will report earnings of ($0.54) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for Omega Therapeutics’ earnings, with estimates ranging from ($0.65) to ($0.48). Omega Therapeutics posted earnings of ($3.36) per share in the same quarter […]